<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>
Agreement with Biogen to buyout Biogen’s (50% -1 share) stake in Samsung Bioepis Joint Venture for up to USD $2.3 billion Transaction projected to be accretive to earnings in 2022 and thereafter, fully capitalizing on the high growth potential of Samsung Bioepis Expected to accelerate growth in biosimilars and novel therapeutics R&D Purchase to be funded through a portion of KRW 3 trillion paid-in capital increase, focused on investment in Samsung Biologics’ future growth INCHEON, South Korea, Jan. 27, 2022 /PRNewswire/ — Samsung Biologics (KRX: 207940.KS) announced today that it has reached an agreement with Biogen for the buyout of Biogen’s stake in the Samsung Bioepis joint venture for USD $2.3 billion. The transaction is expected to boost earnings growth of Samsung Biologics on a consolidated basis, fully capitalizing on Samsung Bioepis’ growth outlook.
...read full article on PRNewsWire
